Urology Times staff

“I think it's the responsibility of the physician to really take on educating and counseling and setting clear expectations and that way, when complications do arise, patients are better equipped, and they have a more favorable outcome,” says Ariana Matz, MD.

“What I found exciting was that the extent to which a…PI-RADS 4 score saved biopsies without really affecting the likelihood of detecting clinically significant tumor,” says Stella K. Kang, MD.

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”

Arjun V. Balar, MD, describes the 2 “very distinct patient populations” of separate phase 2 studies from ASCO 2021 involving the treatment pembrolizumab (Keytruda).

Brian T. Helfand, MD, PhD, discusses how the precision of genomic testing data can alleviate the accuracy issues associated with PSA testing for screening and monitoring prostate cancer.

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, explains the increased significance of genomic testing in the field of prostate cancer.

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses findings from the pivotal EV-301 trial of enfortumab vedotin.

"Same-day discharge is safe and feasible across a broad spectrum of FPMRS cases," says Jacqueline Zillioux, MD.

In this video, 5 urologists each weigh in on whether they listen to music in the OR, and if so, what they like to listen to.

Vinayak G. Wagaskar, MBBS, shares potential explanations for the obesity paradox in patients with metastatic castration-resistant prostate cancer and provides next steps for exploring this phenomenon.

Terrence Regan, MD, also discusses appropriate use criteria for advanced imaging from the Centers for Medicare & Medicaid Services.

“There's a lot that urologists can pick up on how to better interact with their patients,” says David King Keller, PhD, of Active Surveillance Patients International.

Evangelia Sereti, MSc, PhD, discusses the design/methodology and results of a preclinical study exploring the combination of the PARP inhibitor olaparib plus the novel agent NOV202 in BRCA1/2-mutated prostate cancer cells.

“[Prior authorization is] becoming a bigger and bigger problem for each practice,” says urologist Terrence Regan, MD.

Vinayak G. Wagaskar, MBBS, explains the “obesity paradox”—improved survival outcomes in patients with a high body mass index—that has been observed in patients with genitourinary malignancies, including prostate cancer.

Bradley McGregor, MD, explains how despite the groundbreaking immunotherapy-based advances in metastatic renal cell carcinoma, unmet medical needs remain.

“[Prior authorization has] become part of our everyday practicing life, but it does very little to advance quality of care,” says Terrence Regan, MD.

“The key message from this abstract is that the time duration for starting avelumab [Bavencio] maintenance didn't really affect the outcomes,” says Shilpa Gupta, MD.

“The side that can take…complex issues and make them simple…is likely going to be the side that wins in a case,” says Kenton H. Steele, Esq.

Shilpa Gupta, MD, discusses several recent studies in the metastatic urothelial carcinoma space.

Urologists Steven M. Wahle, MD, and Henry Rosevear, MD, catch up with each other in this wide-ranging conversation.

Yousef Zakharia, MD, discusses the design and results of a phase 2 trial that explored concurrent treatment with radiation and the PD-L1 inhibitor durvalumab followed by adjuvant durvalumab in patients with urothelial cancer.

Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.

Risa Wong, MD, discusses the sequencing of treatments in the metastatic urothelial carcinoma armamentarium, including chemotherapy, immune checkpoint inhibitors, and antibody-drug conjugates.

Although women represent an increasing percentage of the urology workforce, they continue to be underrepresented in receiving recognition awards from the American Urological Association.

"I think [at] the 2021 ASCO annual meeting, we saw a lot of novel data focusing on bladder-preservation approaches," says Shilpa Gupta, MD.

Miron presented a study at the 2021 ASCO Annual Meeting that explored the influence of first-line chemotherapy choice on survival outcomes in patients who received immunotherapy in the second-line setting.

In this video, Shilpa Gupta, MD, discusses the rapidly evolving world of research on urothelial carcinoma.

Miron et al specifically compared the choice between frontline cisplatin plus gemcitabine versus frontline carboplatin plus gemcitabine in patients with advanced urothelial carcinoma.

Between 40% and 50% of patients with mCRPC have loss in PTEN, which is associated with worse prognosis and reduced benefit from AR blockade.